I. Introduction
Liposarcoma (LPS) is the most common soft tissue sarcoma and accounts for approximately 16% of all the sarcomas [1]. Current methods for diagnosis rely on invasive tissue biopsies as standalone procedures or in combination with imaging approaches to identify tumor mass and location [2]. One of the emerging molecular targets for clinicians is the evaluation of the MDM2 DNA sequence copy numbers to distinguish between dedifferentiated liposarcoma (DDLPS) and benign lipoma [3], [4].